Immuno-oncology

The remarkable results being achieved by immuno-oncology treatments in the last 12 months has been a game-changer for the field, and KWS BioTest’s expertise in immunology can help ensure your programme will be part of this exciting development.

Developments in Immuno-oncology

CEO Dr Robin Brown and CSO Professor Neil Williams discuss the exciting recent developments in immuno-oncology.

Read video transcription

Recent clinical successes in immuno-oncology have highlighted the important role that the immune system can play in mediating the destruction of human tumours.

The complexity of the tumour microenvironment provides many prospective targets for modulation in order to make the immune system more effective against the tumour. This is an environment we understand. We have the assays and systems that will allow you to look at these targets and to examine how modifying them will impact tumour survival. In addition, we have the capabilities and knowledge to help you access existing models and develop new ones.

Here at KWS BioTest, we use a broad range of techniques, focusing on primary human cell assays, to look at immune system targets. We have developed assays for the major cells influencing the tumour microenvironment as illustrated by specific examples shown in this section.

KWS BioTest immuno-oncology blog

Read our latest blog posts on immuno-oncology

Read posts
We measure your drug’s ability to enhance T-cell activity or reverse exhaustion using a variety of assays
Asset 2

Spotlight assay

Primary human T-cell cultures are used in order to demonstrate the immune potentiating effects of existing and novel immune checkpoint inhibitors.

Asset 1
Asset 2

Spotlight assay

Co-culture of primary human T-cells with tumour cells/supernatants induces an exhausted phenotype. KWS BioTest screens novel compounds for their ability to block tumour cell mediated effects or reverse T-cell exhaustion in translational assays.

Asset 1
We have validated a range of assays that enable you to assess the effects of compounds as modulators of the immune suppressive tumour microenvironment.
Asset 2

Spotlight assay

KWS BioTest induces primary human macrophages into immunosuppressive, pro-angiogenic TAM-like (Tumor-associated macrophages) cells by following co-culture with human tumour cells/supernatants. Agents designed to enhance the inflammatory potential of macrophages can be tested using these, or conventional M2a or M2b macrophages and dendritic cells.

Asset 1
Asset 2

Spotlight assay

Modulation of tryptophan metabolism by IDO and TDO is an important mechanism by which tumours limit T cell activation. Novel modulators of IDO and TDO are tested in assays which assess tryptophan metabolism and its functional consequences on T cell function using primary human cells.

Asset 1